The approval of the first two monoclonal antibodies targeting CD38 (daratumumab) and
SLAMF7 (elotuzumab) in late 2015 for treating relapsed and refractory multiple myeloma …

Purpose Understanding the etiology of cancer-related fatigue (CRF) is critical to identify
targets to develop therapies to reduce CRF burden. The goal of this systematic review was …

The incorporation of novel agents and monoclonal antibody-based therapies into the
treatment of multiple myeloma (MM) has significantly improved long-term patient survival …

© 2016 D'Amico et al. This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after the …

Purpose Cancer-related fatigue (CRF) is the most common symptom experienced by cancer
survivors. It is a multidimensional symptom affecting physical, emotional, and/or cognitive …

Multiple myeloma is a hematologic malignancy of plasma cells that causes bone-destructive
lesions and associated skeletal-related events (SREs). The pathogenesis of myeloma …

Multiple Myeloma (MM) is a systemic hematologic disease due to uncontrolled proliferation
of monoclonal plasma cells (PC) in bone marrow (BM). Emerging in other solid and liquid …

The extracellular matrix (ECM) is a major component of the tumor microenvironment,
contributing to the regulation of cell survival, proliferation, differentiation and metastasis. In …

Multiple myeloma is an incurable hematologic cancer characterized by the clonal
proliferation of malignant plasma cells within the bone marrow. Numerous studies suggest …

Immunomodulatory drugs and monoclonal antibody-based immunotherapies have
significantly improved the prognosis of the patients with multiple myeloma (MM) in the recent …